Fig. 4

FAO inhibition sensitised Linc01056-knockdowned HCC cells upon sorafenib treatment. (a) Knockdown of Linc01056 resulted in an increase in fatty acid uptake in HCC cells, which was further augmented under sorafenib treatment. FAO suppression by etomoxir (b) increased cytotoxicity of sorafenib, (c) suppressed colonic capacity, and (d) induced apoptosis in HCC cells with Linc01056 knockdown. FAO suppression by etomoxir (e & f) reduced in vivo tumour growth and (g & h) end-point tumour size, (i) increased expression of cell apoptosis marker cleaved caspase-3 and reduced the cell proliferation marker Ki67 in sorafenib-treated in vivo HCC tumours without Linc01056 knockdown. *p < 0.05, **p < 0.01, ***p < 0.001